Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
Top Page
Qyuns Therapeutics Co., Ltd. Class H
(2509)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$22.00
▼(-23.02% Downside)
Action:ReiteratedDate:11/28/25
The overall score of 46 for Qyuns Therapeutics is primarily driven by weak financial performance, with significant losses and high leverage overshadowing impressive revenue growth. Technical indicators show mixed signals with neutral momentum, while valuation remains speculative due to negative earnings. Financial risks are the most critical factor, with limited upside from technicals or valuation at this stage.
Positive Factors
Revenue Growth
The substantial revenue growth indicates strong market demand and successful product adoption, which can support long-term business expansion and investment in R&D.
Negative Factors
High Leverage
High leverage can increase financial risk and limit flexibility, potentially impacting the company's ability to invest in growth or weather economic downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The substantial revenue growth indicates strong market demand and successful product adoption, which can support long-term business expansion and investment in R&D.
Read all positive factors
Qyuns Therapeutics Co., Ltd. Class H (2509) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.68B
Dividend YieldN/A
Average Volume (3M)305.01K
Price to Earnings (P/E)―
Beta (1Y)0.61
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees339
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.68
Shares Outstanding227,071,600
10 Day Avg. Volume194,489
30 Day Avg. Volume305,010
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)6.64
Price to Sales (P/S)9.58
P/FCF Ratio-8.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$31.58Price Target Upside10.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.72
Revenue Forecast (FY)HK$578.85M
Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Qyuns Therapeutics Co., Ltd. Class H (2509) is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases, particularly in the fields of oncology and autoimmune disorders. The company specializ...
How the Company Makes Money
Qyuns Therapeutics generates revenue primarily through the sale of its biopharmaceutical products, which includes both proprietary drugs and those developed in collaboration with strategic partners. The company's revenue model includes direct sale...
Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 320.36M | 158.79M | 14.75M | 9.66M | 21.35M |
| Gross Profit | 232.06M | 92.19M | 14.75M | -25.85M | -9.56M |
| EBITDA | -156.69M | -311.82M | -484.12M | -295.51M | -155.65M |
| Net Income | -191.79M | -335.57M | -507.75M | -298.19M | -411.04M |
Balance Sheet | |||||
| Total Assets | 1.13B | 983.88M | 795.58M | 1.16B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 558.90M | 556.55M | 377.25M | 689.57M | 620.44M |
| Total Debt | 635.93M | 527.60M | 346.06M | 295.25M | 290.26M |
| Total Liabilities | 916.32M | 762.83M | 494.63M | 419.55M | 444.45M |
| Stockholders Equity | 226.36M | 228.98M | 324.54M | 641.72M | 670.35M |
Cash Flow | |||||
| Free Cash Flow | -213.39M | -186.09M | -308.63M | -301.70M | -228.64M |
| Operating Cash Flow | -211.00M | -186.09M | -300.68M | -275.23M | -157.60M |
| Investing Cash Flow | 109.12M | -25.23M | 243.11M | -5.70M | -306.69M |
| Financing Cash Flow | 133.17M | 351.81M | 61.21M | 211.49M | 281.48M |
Qyuns Therapeutics Co., Ltd. Class H Technical Analysis
Positive
28.58
Price Trends
19.31
Positive
19.86
Positive
21.55
Negative
Market Momentum
0.34
Negative
59.72
Neutral
73.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2509, the sentiment is Positive. The current price of 28.58 is above the 20-day moving average (MA) of 18.53, above the 50-day MA of 19.31, and above the 200-day MA of 21.55, indicating a neutral trend. The MACD of 0.34 indicates Negative momentum. The RSI at 59.72 is Neutral, neither overbought nor oversold. The STOCH value of 73.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2509.
Qyuns Therapeutics Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
52 Neutral | HK$3.74B | -13.26 | 11.40% | ― | 79.98% | -3.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$4.68B | -54.41 | -48.44% | ― | ― | ― | |
44 Neutral | HK$758.18M | -6.45 | 191.92% | ― | ― | 83.89% | |
43 Neutral | HK$1.23B | -2.47 | -27.44% | ― | -57.84% | 24.58% | |
41 Neutral | HK$966.22M | -1.73 | -75.15% | ― | 2.45% | 2.58% |
* Healthcare Sector Average
HK:2509
Qyuns Therapeutics Co., Ltd. Class H
20.60
12.70
160.76%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.99
3.41
215.82%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.19
0.76
53.15%
HK:2197
Clover Biopharmaceuticals Ltd.
2.88
2.68
1340.00%
HK:2257
Sirnaomics Ltd.
6.91
3.93
131.88%
HK:6628
Transcenta Holding Limited
2.79
1.71
158.33%
Qyuns Therapeutics Co., Ltd. Class H Corporate Events
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
Jan 7, 2026
Qyuns Therapeutics Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, develops and commercialises therapeutic products and serves investors in the Hong Kong capital market through its H-share listing. The company’s board has in...
Qyuns Therapeutics Out-Licenses QX027N Globally in Deal Worth Up to US$700 Million
Dec 22, 2025
Qyuns Therapeutics has signed a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Switzerland-based Windward Bio Group AG, granting LE2025 exclusive rights to develop and commercialize its long-acting anti-TSLPxIL-13...
Qyuns Therapeutics Shareholders Approve Renewal of Caps for Connected Transactions at EGM
Dec 19, 2025
Qyuns Therapeutics Co., Ltd. reported that its extraordinary general meeting held on 19 December 2025 in Taizhou, Jiangsu, was duly convened in compliance with PRC law and the company’s articles, with a turnout representing over 70% of H sha...
Qyuns Therapeutics Advances Global Clinical Trials with Key Approval
Dec 9, 2025
Qyuns Therapeutics Co., Ltd. has received approval from the Human Research Ethics Committee in Australia for a Phase I clinical trial of its bispecific antibody, QX030N/CLD-423, marking a significant milestone in its international clinical develop...
Qyuns Therapeutics Announces EGM to Discuss Key Resolutions
Dec 3, 2025
Qyuns Therapeutics Co., Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 19, 2025, to discuss and approve key resolutions. These include the renewal of the New Annual Caps for financial years 2026 to 2028 under the ...
Qyuns Therapeutics Announces EGM and H Shares Register Closure
Dec 1, 2025
Qyuns Therapeutics Co., Ltd., a company incorporated in the People’s Republic of China, has announced the closure of its H shares register from December 16 to December 19, 2025, in preparation for an extraordinary general meeting (EGM) sched...
Qyuns Therapeutics’ QX027N Antibody Gains Clinical Trial Approvals
Nov 13, 2025
Qyuns Therapeutics Co., Ltd. announced that its long-acting bispecific antibody, QX027N, has received clinical trial approvals for treating asthma and atopic dermatitis, marking a significant milestone in its bispecific antibody pipeline. This dev...
Qyuns Therapeutics Renews Annual Caps for QX001S Framework Agreement
Nov 11, 2025
Qyuns Therapeutics Co., Ltd. has announced the renewal of annual caps for the QX001S Framework Agreement with Zhongmei Huadong, a substantial shareholder holding 15.85% of the company’s issued share capital. This renewal pertains to the comm...
Qyuns Therapeutics Initiates Share Repurchase to Boost Market Confidence
Nov 10, 2025
Qyuns Therapeutics Co., Ltd. announced a voluntary on-market share repurchase, indicating that the board believes the current share price undervalues the company’s worth. The repurchase of 549,800 ordinary shares, valued at approximately HK$...
Qyuns Therapeutics Partners with Roche for Global Development of QX031N
Oct 28, 2025
Qyuns Therapeutics Co., Ltd. has entered into a global exclusive license agreement with Roche, granting Roche the rights to develop, manufacture, and commercialize QX031N. This agreement includes an upfront payment of $75 million to Qyuns and pote...
Qyuns Therapeutics Announces Promising Phase III Results for Ankylosing Spondylitis Treatment
Oct 28, 2025
Qyuns Therapeutics Co., Ltd. has announced successful Phase III clinical trial results for Crusekitug (QX002N), a treatment for ankylosing spondylitis, presented at the 2025 ACR Annual Meeting. The trial demonstrated significant improvements in cl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.